Picibanil
Picibanil é uma mistura de estreptococos do grupo A com propriedades anti-neoplásicas utilizado no tratamento de higroma cístico (linfangioma).[1]
Referências[editar | editar código-fonte]
- ↑ Elena Rebuffini,1 Luca Zuccarino,2 Emma Grecchi,1 Francesco Carinci,1 and Vittorio Emanuele Merulla (2012). «Picibanil (OK-432) in the treatment of head and neck lymphangiomas in children». Dent Res J (Isfahan). 9(Suppl 2): S192–S196. PMC 3692172
. PMID 23814582. doi:10.4103/1735-3327.109752
Bibliografia[editar | editar código-fonte]
- Rachel Airley (2009). Cancer chemotherapy. [S.l.]: Wiley-Blackwell. ISBN 0-470-09254-8
- Wood, Miriam, David Brighton (2005). The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team. St. Louis, Mo: Elsevier Churchill Livingstone. ISBN 0-443-07101-2
- Fergus Macbeth, Hanna, Louise, Crosby, Tom (2008). Practical clinical oncology. Cambridge, UK: Cambridge University Press
- Perry, Michael J. (2008). The Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins
- Faguet GB (2005). The War on Cancer. [S.l.]: Springer. p. 71. ISBN 1-4020-3618-3
- Hirsch J (setembro de 2006). «An anniversary for cancer chemotherapy». JAMA. 296 (12): 1518–20. PMID 17003400. doi:10.1001/jama.296.12.1518
- Huang ES (2000). Internal medicine: handbook for clinicians, resident survival guide. Arlington, VA: Scrub Hill Press. p. 130. ISBN 978-0-9645467-5-2
- Randall, [edited by] William J. Hoskins, Carlos A. Perez, Robert C. Young, Richard R. Barakat, Maurie Markman, Marcus E. (2005). Principles and practice of gynecologic oncology 4. ed. Baltimore, Md.: Lippincott Williams & Wilkins. pp. 93–94. ISBN 0-7817-4689-2